retatrutide stock price Cost Could This Near Trillion-Dollar Stock
Description
ARTICLES Another Triumph: Lillys triple G agonist scores in obesity Posting another win for its triple G agonist, Eli Lilly and Co
The drug pipelines have diversified
Meaning Medicare Part D coverage of GLP-1RAs to treat obesity would lead to a substantial net increase in future Medicare spending, and policymakers should leverage a comprehensive range of strategies, including further price reductions resulting from Medicares drug price negotiation under the Inflation Reduction Act, lower cost strategies to prevent weight regain, and reductions in spending on unnecessary care
Both compounds significantly reduce liver fat, but retatrutide has stronger data
Do payers switch after patent expiry immediately
June 27, 2024.
